지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease. The prevalence of NAFLD isgrowing gradually worldwide with increases in obesity, sedentary lifestyles, and an unbalanced diet. NAFLD ranges from simplesteatosis without inflammation to steatohepatitis that can progress to cirrhosis. There is no single effective treatment that haswidespread effects in NAFLD. The cornerstone of treatment is lifestyle modification, including weight reduction, diet, and physicalactivity. An approximately 7-10% weight reduction via diet or physical activity can improve the liver histopathology. Risk factorsfor NAFLD include a high-calorie diet, high-lipid diet, high-carbohydrate diet, saturated fatty acids, trans fatty acids, cholesterol,high fructose intake, and low-choline diet. Factors that protect against NAFLD include a low-calorie diet, low-carbohydrate diet,low-lipid diet, monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), dietary fiber, coffee, green tea, and lightalcohol consumption. Physical activity also helps to manage NAFLD with or without weight reduction. Recent reports found thatresistance training is as effective as aerobic training. Lifestyle modification has very low compliance. To maintain a treatmentprogram, a multidisciplinary team approach is required that includes physicians, dietitians, physical trainers, and psychologists.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Andersen T / 1991 / Hepatic effects of dietary weight loss in morbidly obesesubjects / J Hepatol 12 : 224 ~ 229
Carvalhana S / 2012 / Improvingdietary patterns in patients with nonalcoholic fatty liverdisease / Curr Opin Clin Nutr Metab Care 15 : 468 ~ 473
Chalasani N / 2012 / The diagnosisand management of non-alcoholic fatty liver disease:practice Guideline by the American Association for theStudy of Liver Diseases, American
Harrison SA / 2004 / A pilot study of orlistat treatment in obese, non-alcoholicsteatohepatitis patients / Aliment Pharmacol Ther 20 : 623 ~ 628
Harrison SA / 2009 / Orlistat for overweight subjects with nonalcoholic steatohepatitis:a randomized, prospective trial / Hepatology 49 : 80 ~ 86
Carvalhana S / 2012 / Improvingdietary patterns in patients with nonalcoholic fatty liverdisease / Curr Opin Clin Nutr Metab Care 15 : 468 ~ 473
Chalasani N / 2012 / The diagnosisand management of non-alcoholic fatty liver disease:practice Guideline by the American Association for theStudy of Liver Diseases, American
Harrison SA / 2004 / A pilot study of orlistat treatment in obese, non-alcoholicsteatohepatitis patients / Aliment Pharmacol Ther 20 : 623 ~ 628
Harrison SA / 2009 / Orlistat for overweight subjects with nonalcoholic steatohepatitis:a randomized, prospective trial / Hepatology 49 : 80 ~ 86
이 논문의 저자 정보
최근 본 자료
댓글(0)
0